



Tokyo, November 5, 2019

FOR IMMEDIATE RELEASE

Torii has entered into a License Agreement with BioCryst Pharmaceuticals, Inc. for BCX7353 for the prevention of HAE attacks

Torii Pharmaceutical Co., Ltd. (Torii) (TSE:4551) announces today that the company has entered into a license agreement with BioCryst Pharmaceuticals, Inc. (BioCryst) (Nasdaq: BCRX) for exclusive marketing rights in Japan to the plasma kallikrein inhibitor BCX7353 that BioCryst has developed for the prevention of hereditary angioedema (HAE) attacks

HAE is a genetic disorder that develops by excess bradykinin formation as a result of C1 inhibitor deficiency and causes sudden edema to various regions such as extremities, face or digestive organ, resulting in swelling or abdominal pain, etc. that interferes with patients' daily life.

BCX7353 is a new oral agent that is expected to prevent an attack of HAE by specifically blocking the bradykinin-forming enzyme. BioCryst is currently performing a Phase 3 clinical trial in Japan. In a Phase 3 clinical trial that BioCryst previously performed in the US, Canada and Europe, a clinically important and statistically significant reduction of the number of HAE attacks by BCX7353 compared to placebo has been confirmed, and BCX7353 was also safe and generally well-tolerated.

BCX7353 is designated as an orphan drug and received SAKIGAKE Designation. BioCryst plans to apply for marketing approval in the first quarter of 2020 in Japan, following completion of the Phase 3 trial in Japan. Torii will market and sell BCX7353 after the marketing approval.

According to the Agreement, Torii will pay BioCryst an upfront payment of US\$22 million, and up to US\$20 million upon the achievement of certain milestones. In addition, Torii will pay royalties to BioCryst based on product sales.

The effects of the conclusion of the license agreement on the business performance of Torii's in this fiscal year will be immaterial.

About BioCryst Pharmaceuticals, Inc.

BioCryst discovers novel, oral small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.

For more information, please visit the Company's website at www.BioCryst.com.

Contact for Torii Pharmaceutical Co., Ltd.:
Corporate Planning Department
(Public Relations)
Torii Pharmaceutical Co., Ltd.
Tokyo: +81-3-3231-6814